EU regulator declines to recommend Amylyx' ALS therapy
Oct 13 (Reuters) - Amylyx Pharmaceuticals said on Friday EU regulator declined to recommend marketing authorisation of the company's therapy to treat amyotrophic lateral sclerosis.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Sherry Jacob-Phillips)